Ulcerative colitis-associated colorectal cancer

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16389-16397

  Yashiro, Masakazu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoprevention; Dysplasia; Risk factor; Surveillance colonoscopy; Ulcerative colitis associated colorectal cancer

Indexed keywords

ACETYLSALICYLIC ACID; MESALAZINE; MICRORNA; MICRORNA 124; MICRORNA 155; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE; STEROID; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; URSODEOXYCHOLIC ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE DURATION; DYSPLASIA; FAMILY HISTORY; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MICROSATELLITE INSTABILITY; ONSET AGE; PANCOLITIS; PRIMARY SCLEROSING CHOLANGITIS; SIGNET RING CARCINOMA; SYSTEMATIC REVIEW (TOPIC); TOTAL COLON RESECTION; ULCERATIVE COLITIS; ANIMAL; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; COMPLICATION; EARLY DIAGNOSIS; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84918816499     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16389     Document Type: Article

References (107)

1. Dobbins WO. Dysplasia and malignancy in inflammatory bowel disease. Annu Rev Med 1984; 35: 33-48 [PMID: 6372661 DOI: 10.1146/ annurev.me.35.020184.000341]
2. Isbell G, Levin B. Ulcerative colitis and colon cancer. Gastroenterol Clin North Am 1988; 17: 773-791 [PMID: 3068141]
3. Chambers WM, Warren BF, Jewell DP, Mortensen NJ. Cancer surveillance in ulcerative colitis. Br J Surg 2005; 92:928-936 [PMID: 16034807]
4. Grivennikov SI. Inflammation and colorectal cancer: colitisassociated neoplasia. Semin Immunopathol 2013; 35: 229-244 [PMID: 23161445 DOI: 10.1007/s00281-012-0352-6]
5. Gyde S, Prior P, Dew MJ, Saunders V, Waterhouse JA, Allan RN. Mortality in ulcerative colitis. Gastroenterology 1982; 83: 36-43 [PMID: 7075944]
6. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a casecontrol study. Am J Epidemiol 1990; 132: 1111-1119 [PMID: 2260543]
7. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103:1444-1451 [PMID: 1358741]
8. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862 [PMID: 11241255 DOI: 10.1002/1097-0142(20010215)91]
9. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
10. Karlén P, Löfberg R, Broström O, Leijonmarck CE, Hellers G, Persson PG. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999; 94: 1047-1052 [PMID: 10201481 DOI: 10.1111/ j.1572-0241.1999.01012.x]
11. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, Lofberg R, Brostrom O, Hellers G. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29: 206-217 [PMID: 3345932 DOI: 10.1136/gut.29.2.206]
12. Broström O, Löfberg R, Nordenvall B, Ost A, Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol 1987; 22: 1193-1199 [PMID: 3433007 DOI: 10.3109/00365528708996463]
13. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 31: 800-806 [PMID: 2370015 DOI: 10.1136/gut.31.7.800]
14. Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, Rozen P, Lilos P. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988; 94: 870-877 [PMID: 3345886]
15. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med 1987; 316: 1654-1658 [PMID: 3295551 DOI: 10.1056/NEJM198706253162609]
16. Löfberg R, Broström O, Karlén P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis-a 15-year follow-up study. Gastroenterology 1990; 99: 1021-1031 [PMID: 2394325]
17. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-211 [PMID: 16534422 DOI: 10.1097/01.MIB.0000217770.21261.ce]
18. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a populationbased cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004; 2: 1088-1095 [PMID: 15625654 DOI: 10.1016/51542-3565(04)00543-9]
19. Rutter MD, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible costs and benefits of ulcerative colitis surveillance: a patient survey. Dis Colon Rectum 2006; 49: 1177-1183 [PMID: 16763757 DOI: 10.1007/s10350-006-0546-x]
20. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136:1561-157; quiz 1561-157; [PMID: 19422077]
21. Männinen P, Karvonen AL, Huhtala H, Aitola P, Hyöty M, Nieminen I, Hemminki H, Collin P. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years, J Crohns Colitis 2013; 7: e551-e557 [PMID: 23619008 DOI: 10.1016/ j.crohns.2013.04.003]
22. Hata K, Watanabe T, Kazama S, Suzuki K, Shinozaki M, Yokoyama T, Matsuda K, Muto T, Nagawa H. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer 2003; 89: 1232-1236 [PMID: 14520452 DOI: 10.1038/ sj. bjc.6601247]
23. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 645-659 [PMID: 24612141 DOI: 10.1111/apt.12651]
24. Mellemkjaer L, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH. Crohn's disease and cancer risk (Denmark). Cancer Causes Control 2000; 11: 145-150 [PMID: 10710198 DOI: 10.1023/A:1008988215904]
25. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-359 [PMID: 1975343 DOI: 10.1016 /0140-6736(90)91889-1]
26. Persson PG, Karlén P, Bernell O, Leijonmarck CE, Broström O, Ahlbom A, Hellers G. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107: 1675-1679 [PMID: 7958678]
27. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut 1994; 35: 1507-1508 [PMID: 7828962 DOI: 10.1136/ gut.35.11.1507]
28. Herline AJ, Meisinger LL, Rusin LC, Roberts PL, Murray JJ, Coller JA, Marcello PW, Schoetz DJ. Is routine pouch surveillance for dysplasia indicated for ileoanal pouches? Dis Colon Rectum 2003; 46: 156-159 [PMID: 12576887 DOI: 10.1097/01. DCR.0000049346.48395.4D]
29. O'Riordain MG, Fazio VW, Lavery IC, Remzi F, Fabbri N, Meneu J, Goldblum J, Petras RE. Incidence and natural history of dysplasia of the anal transitional zone after ileal pouchanal anastomosis: results of a five-year to ten-year follow-up. Dis Colon Rectum 2000; 43: 1660-1665 [PMID: 11156448 DOI: 10.1007/BF02236846]
30. Averboukh F, Ziv Y, Kariv Y, Zmora O, Dotan I, Klausner JM, Rabau M, Tulchinsky H. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. Colorectal Dis 2011; 13: 1230-1235 [PMID: 21689324 DOI: 10.1111/j.l463-1318.2011.02639.x]
31. Sugita A, Greenstein AJ, Ribeiro MB, Sachar DB, Bodian C, Panday AK, Szporn A, Pozner J, Heimann T, Palmer M. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg 1993; 218:189-195 [PMID: 8342999]
32. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 2011; 17: 802-808 [PMID: 20848547 DOI: 10.1002/ibd.21365]
33. Kavanagh DO, Carter MC, Keegan D, Doherty G, Smith MJ, Hyland JM, Mulcahy H, Sheahan K, O'Connell PR, O'Donoghue DP, Winter DC. Management of colorectal cancer in patients with inflammatory bowel disease. Tech Coloproctol 2014; 18: 23-28 [PMID: 23407916 DOI: 10.1007/ slOl51-013-0981-3]
34. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120 [PMID: 7912678]
35. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130: 1941-1949 [PMID: 16762617 DOI: 10.1053/ j.gastro.2006.03.028]
36. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14: 378-389 [PMID: 18200660 DOI: 10.3748/wjg.14.378]
37. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]
38. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233 [PMID: 2215606 DOI: 10.1056/ NEJM199011013231802]
39. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-81.e1; quiz e13-4 [PMID: 22522090 DOI: 10.1053/ j.gastro.2012.04.016]
40. Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009; 44: 46-55 [PMID: 18609187 DOI: 10.1080/00365520801977568]
41. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53: 1590-1599 [PMID: 21351115 DOI: 10.1002/ hep.24247]
42. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408 [PMID: 7590655]
43. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endose 2002; 56: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]
44. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-1362 [PMID: 11313305 DOI: 10.1053/ gast.2001.24052]
45. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, L indor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998; 115: 1079-1083 [PMID: 9797361 DOI: 10.1016/50016-5085(98)70077-0]
46. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 2001; 357: 262-266 [PMID: 11214128 DOI: 10.1016/50140-6736(00)03612-6]
47. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, Waldman FM. Genomic instability is an early event during the progression pathway of ulcerativecolitis-related neoplasia. Am J Pathol 1999; 154: 1825-1830 [PMID: 10362807 DOI: 10.1016/50002-9440(10)65438-7]
48. Cottliar A, Fundia A, Boerr L, Sambuelli A, Negreira S, Gil A, Gómez JC, Chopita N, Bernedo A, Slavutsky I. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol 2000; 95: 2301-2307 [PMID: 11007232 DOI: 10.HH/j.1572-0241.2000.02315.x]
49. Lovig T, Andersen SN, Clausen OP, Rognum TO. Microsatellite instability in long-standing ulcerative colitis. Scand J Gastroenterol 2007; 42: 586-591 [PMID: 17454879 DOI: 10.1080 /00365520601013747]
50. Fujiwara I, Yashiro M, Kubo N, Maeda K, Hirakawa K. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum 2008; 51: 1387-1394 [PMID: 18546042 DOI: 10.1007/sl0350-008-9212-9]
51. Shigaki K, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R, Takenoshita S. Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. Hum Pathol 2013; 44: 2393-2399 [PMID: 24029705 DOI: 10.1016/j.humpath.2013.06.008]
52. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, Meitzer SJ. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hyperméthylation and diminished expression of the DNA mismatch repair gene, hMLHl. Cancer Res 2000; 60: 4864-4868 [PMID: 10987299]
53. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Forschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998; 58: 3942-3945 [PMID: 9731506]
54. Moriyama T, Matsumoto T, Nakamura S, Jo Y, Mibu R, Yao T, Iida M. Hyperméthylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis Colon Rectum 2007; 50: 1384-1392 [PMID: 17665255 DOI: 10.1007/1 0350-007-0302-x]
55. Maeda O, Ando T, Watanabe O, Ishiguro K, Ohmiya N, Niwa Y, Goto H. DNA hypermethylation in colorectal neoplasms and inflammatory bowel disease: a mini review. Inflammopharmacology 2006; 14: 204-206 [PMID: 17093903 DOI: 10.1007/sl0787-006-1540-6]
56. Chen WX, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. World J Gastrointest Pathophysiol 2014; 5: 63-70 [PMID: 24891977 DOI: 10.4291/wjgp.v5.i2.63]
57. Ueda Y, Ando T, Nanjo S, Ushijima T, Sugiyama T. DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. Dig Dis Sci 2014; 59: 2444-2451 [PMID: 24825593 DOI: 10.1007/ S10620-014-3193-4]
58. Svrcek M, El-Murr N, Wanherdrick K, Dumont S, Beaugerie L, Cosnes J, Colombel JF, Tiret E, Fléjou JF, Lesuffleur T, Duval A. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis 2013; 34: 828-834 [PMID: 23288924 DOI: 10.1093/ carcin/bgs408]
59. Thorsteinsdottir S, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat Rev Gastroenterol Hepatol 2011; 8: 395-404 [PMID: 21647200 DOI: 10.1038/nrgastro.2011.96]
60. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-285 [PMID: 12671666 DOI: 10.1038/nrcl046]
61. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-370 [PMID: 10688856 DOI: 10.1093/carcin/21.3.361]
62. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease, Clin Invest 1996; 98: 136-141 [PMID: 8690784 DOI: 10.1172/JCI118757]
63. D'Incà R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 2004; 10: 23-27 [PMID: 15058522 DOI: 10.1097/00054725-200401000-00003]
64. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-968 [PMID: 6629368]
65. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424 [PMID: 8335197]
66. Karlén P, Kornfeld D, Broström O, Löfberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-714 [PMID: 9659169 DOI: 10.1136/gut.42.5.711]
67. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5: Vl-16 [PMID: 15306569 DOI: 10.1136/ gut.2004.043372]
68. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Baden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804]
69. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, Faigel DO, Gan SI, Hirota WK, Lichtenstein D, Qureshi WA, Rajan E, Zuckerman MJ, VanGuilder T, Fanelli RD. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endose 2006; 63: 558-565 [PMID: 16564852 DOI: 10.1016/j.gie.2006.02.005]
70. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]
71. Baden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51 Suppl 5: V10-V12 [PMID: 12221032 DOI: 10.1136/gut.51.suppl-5.vl0]
72. Farraye FA, Odze RD, Baden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-74, 774.el-4; quiz e12-3 [PMID: 20141809 DOI: 10.1053/ j.gastro.2009.12.035]
73. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Hauser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogier G, Stein J, Tilg H, Travis S, Lindsay JO. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33 [PMID: 23040453 DOI: 10.1016/j.crohns.2012.09.005]
74. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2: 63-92 [PMID: 21172196 DOI: 10.1016/ j.crohns.2007.12.001]
75. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 314-321 [PMID: 15735438 DOI: 10.1097/01.MIB.0000160811.76729.d5]
76. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Metaanalysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Eher 2007; 25: 657-668 [PMID: 17311598 DOI: 10.1111/j.1365-2036.2007.03241.x]
77. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-1319 [PMID: 14598247 DOI: 10.1016/ j.gastro.2003.08.023]
78. Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2: 534-541 [PMID: 15224277 DOI: 10.1016/S1542-3565(04)00237-X]
79. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-74 [PMID: 7903776 DOI: 10.1016/50140-6736(94)90813-3]
80. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41: 522-525 [PMID: 9391253 DOI: 10.1136/ gut.41.4.522]
81. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103:1611-1620 [PMID: 1426881]
82. Mitooka H, Fujimori T, Ohno S, Morimoto S, Nakashima T, Ohmoto A, Okano H, Miyamoto M, Oh T, Saeki S. Chromoscopy of the colon using indigo carmine dye with electrolyte lavage solution. Gastrointest Endose 1992; 38: 373-374 [PMID: 1607092 DOI: 10.1016/50016-5107(92)70436-2]
83. Oka S, Tanaka S, Chayama K. Detection of nonpolypoid colorectal neoplasia using magnifying endoscopy in colonic inflammatory bowel disease. Gastrointest Endose Clin N Am 2014; 24: 405-417 [PMID: 24975531 DOI: 10.1016/ j.giec.2014.03.011]
84. Jess T, Frisch M, Simonsen J. Trends in overall and causespecific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013; 11: 43-48 [PMID: 23022699 DOI: 10.1016/j.cgh.2012.09.026]
85. Herrinton LJ, Liu L, Levin TR, Aliisou JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]
86. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371-1385 [PMID: 15233681 DOI: 10.1111/ j.1572-0241.2004.40036.x]
87. Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, Noffsinger A, Huo D, Rubin DT. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1352-1356 [PMID: 20027656 DOI: 10.1002/ibd.21184]
88. Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002; 45: 615-620 [PMID: 12004210 DOI: 10.1007/sl0350-004-6255-4]
89. Kiran RP, Ahmed Ali U, Nisar PJ, Khoury W, Gu J, Shen B, Remzi FH, Hammel JP, Lavery IC, Fazio VW, Goldblum JR. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg 2014; 259: 302-309 [PMID: 23579580 DOI: 10.1097/ SLA.0b013e31828e7417]
90. Chen YX, Qiao L. Adenoma-like and non-adenoma-like dysplasia-associated lesion or mass in ulcerative colitis. J Dig Dis 2013; 14:157-159 [PMID: 23374421 DOI: 10.1111/1751-2980.12043]
91. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol 1998; 22: 275-284 [PMID: 9500769 DOI: 10.1097/ 00000478-199803000-00001]
92. Yashiro M, Laghi L, Saito K, Carethers JM, Slezak P, Rubio C, Hirakawa K, Boland CR. Serrated adenomas have a pattern of genetic alterations that distinguishes them from other colorectal polyps. Cancer Epidemiol Biomarkers Prev 2005; 14: 2253-2256 [PMID: 16172239 DOI: 10.1158/1055-9965. EPI-04-0790]
93. Johnson DH, Khanna S, Smyrk TC, Loftus EV, Anderson KS, Mahoney DW, Ahlquist DA, Kisiel JB. Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. Aliment Pharmacol Ther 2014; 39: 1408-1417 [PMID: 24779703 DOI: 10.1111/ apt.12774]
94. Bossard C, Denis MG, Bézieau S, Bach-Ngohou K, Bourreille A, Laboisse CL, Mosnier JF. Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncol Rep 2007; 18:1093-1097 [PMID: 17914558]
95. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2014; 345: 235-241 [PMID: 23941831 DOI: 10.1016/ j.canlet.2013.07.032]
96. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-609 [PMID: 10029619 DOI: 10.1016/50016-5085(99)70182-4]
97. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-1578 [PMID: 15994215 DOI: 10.1136/gut.2005.070896]
98. Baden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153 [PMID: 10651654 DOI: 10.1046/j.1365-2036.2000.00698.x]
99. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353 [PMID: 15929768 DOI: 10.1111/j.1572-0241.2005.41442.x]
100. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106: 731-736 [PMID: 21407180 DOI: 10.1038/ajg.2011.50]
101. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-371 [PMID: 17206695 DOI: 10.1002/ ibd.20074]
102. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836 [PMID: 17222314 DOI: 10./1111j.1572-0241.2007.01070.x]
103. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95 [PMID: 11177311 DOI: 10.7326/0 003-4819-134-2-200101160-00008]
104. Sjöqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004; 24: 3121-3127 [PMID: 15510599]
105. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893 [PMID: 12671884 DOI: 10.1053/gast.2003.50156]
106. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44-48 [PMID: 8561142]
107. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038 [PMID: 16618396 DOI: 10.1053/ j.gastro.2005.12.035]